PTC Therapeutics Inc logo

PTC Therapeutics Inc

PTCT
Healthcare|Biotechnology|USA
$84.85
-4.70 (-5.25%)

About

PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.

Stock Price

+71.3%(1Y)

Pipeline Summary

75 total trials
19
Phase 1
36
Phase 2
22
Phase 3
0
Phase 4
Completed: 45Terminated: 17Active: 4Withdrawn: 2Recruiting: 3APPROVED_FOR_MARKETING: 1NOT_YET_RECRUITING: 1NO_LONGER_AVAILABLE: 2

Active Trials (7)

A Study of SmartFlow Magnetic Resonance (MR) Compatible Ventricular Cannula for Administering Eladocagene Exuparvovec to Pediatric Participants
NCT04903288AADC Deficiency
Phase 2Active
Enrollment: 13 participants
Study of L-dopa Treatment in Patients With a Neurodevelopmental Disorder (CTNNB1 Gene)
NCT07614126CTNNB1
N/ARecruiting
Enrollment: 7 participants
A Long-Term Safety Study of PTC923 in Participants With Phenylketonuria
NCT05166161Phenylketonuria
Phase 3Active
Enrollment: 200 participants
Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study
NCT04014530Colorectal Cancer
Phase 1Phase 2Recruiting
Enrollment: 47 participants
A Study of Sepiapterin in Participants With Phenylketonuria (PKU)
NCT06302348Phenylketonuria
Phase 3Recruiting
Enrollment: 56 participants

BioScore

5.2/10
Watchlist

Ownership

Recent Insider Trades

Almstead Neil GregorySELL
2026-07-0746,774 shares @ $87.52
Boulding Mark ElliottSELL
2026-07-065,079 shares @ $85.08
Almstead Neil GregorySELL
2026-06-268,130 shares @ $85.26
Almstead Neil GregorySELL
2026-06-2526,283 shares @ $85.78
Almstead Neil GregorySELL
2026-06-2223,749 shares @ $80.9

Recent News

2026-07-07 16:31:24
2026-06-17 21:00:05
2026-06-16 08:58:49
2026-06-16 04:00:03
2026-06-15 12:00:04
Data last updated: Jul 12, 2026, 07:30 PM